Brief: Microbix Biosystems says consulted with FDA to return its thrombolytic biologic drug to U.S. market
01/05/2017 13:04
May 1 (Reuters) - Microbix Biosystems Inc MBX.TO
* Microbix Biosystems Inc - consulted with FDA regarding
plans to return its thrombolytic biologic drug, kinlytic
urokinase to U.S. market
* Microbix Biosystems Inc - already received expressions of
interest to license or acquire kinlytic and to provide full
funding for its re-launch program
Source text for Eikon: ID:nCCN3NL4ZG
Further company coverage: MBX.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Microbix Biosystems
See all newsCanada's Microbix Q3 revenue rises on higher antigen, QAPs sales
Brief: Microbix Biosystems Q3 Revenue CAD 4.1 Million
Canada's Microbix Biosystems Q2 revenue falls 37% on weaker China sales
Canada's Microbix Q1 revenue down 30% on China sales decline
Brief: Microbix Biosystems Q1 Revenue CAD 4.2 Million